National Bank of Canada FI Has $1.73 Million Stake in Quest Diagnostics Incorporated (NYSE:DGX)

National Bank of Canada FI boosted its holdings in Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 5.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,521 shares of the medical research company’s stock after purchasing an additional 654 shares during the quarter. National Bank of Canada FI’s holdings in Quest Diagnostics were worth $1,732,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mystic Asset Management Inc. bought a new position in Quest Diagnostics in the 4th quarter valued at about $25,000. Wagner Wealth Management LLC bought a new position in Quest Diagnostics in the 4th quarter valued at about $35,000. Sandy Cove Advisors LLC bought a new position in Quest Diagnostics in the 1st quarter valued at about $28,000. Anfield Capital Management LLC increased its holdings in Quest Diagnostics by 1,077.8% in the 4th quarter. Anfield Capital Management LLC now owns 212 shares of the medical research company’s stock valued at $37,000 after buying an additional 194 shares during the period. Finally, NuWave Investment Management LLC bought a new position in Quest Diagnostics in the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Quest Diagnostics Trading Up 1.0 %

DGX opened at $139.38 on Friday. Quest Diagnostics Incorporated has a fifty-two week low of $125.33 and a fifty-two week high of $174.16. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.54 and a quick ratio of 1.42. The firm has a market capitalization of $16.25 billion, a price-to-earnings ratio of 11.60 and a beta of 1.00. The company’s 50 day moving average price is $135.08 and its two-hundred day moving average price is $136.18.

Quest Diagnostics (NYSE:DGXGet Rating) last issued its quarterly earnings results on Thursday, July 21st. The medical research company reported $2.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.26 by $0.10. The firm had revenue of $2.45 billion for the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The company’s revenue for the quarter was down 3.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.18 EPS. As a group, research analysts predict that Quest Diagnostics Incorporated will post 9.69 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 20th. Stockholders of record on Wednesday, July 6th were given a $0.66 dividend. The ex-dividend date of this dividend was Tuesday, July 5th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.89%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 21.96%.

Wall Street Analysts Forecast Growth

Several research firms have commented on DGX. Wells Fargo & Company raised their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, April 25th. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Thursday, July 7th. Bank of America decreased their price target on shares of Quest Diagnostics from $166.00 to $163.00 and set a “buy” rating on the stock in a report on Friday, April 22nd. Finally, UBS Group lifted their price target on shares of Quest Diagnostics from $139.00 to $150.00 in a report on Sunday, April 24th. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $150.33.

Insider Transactions at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 50,604 shares of the business’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $139.97, for a total transaction of $7,083,041.88. Following the transaction, the senior vice president now owns 39,224 shares in the company, valued at approximately $5,490,183.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Michael E. Prevoznik sold 50,604 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $139.97, for a total value of $7,083,041.88. Following the completion of the sale, the senior vice president now directly owns 39,224 shares in the company, valued at approximately $5,490,183.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Timothy M. Ring sold 2,000 shares of the firm’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $133.47, for a total value of $266,940.00. Following the completion of the sale, the director now owns 23,933 shares of the company’s stock, valued at $3,194,337.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 337,012 shares of company stock worth $47,193,071. Company insiders own 1.70% of the company’s stock.

About Quest Diagnostics

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.